Arbit E - Search Results

1

Lessons learned from the clinical development of oral peptides.

Karsdal MA, Riis BJ, Mehta N, Stern W, Arbit E, Christiansen C, Henriksen K. Karsdal MA, et al. Among authors: arbit e. Br J Clin Pharmacol. 2015 May;79(5):720-32. doi: 10.1111/bcp.12557. Br J Clin Pharmacol. 2015. PMID: 25408230 Free PMC article. Review.

2

Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects.

Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, Drewe J. Beglinger C, et al. Among authors: arbit e. Clin Pharmacol Ther. 2008 Oct;84(4):468-74. doi: 10.1038/clpt.2008.35. Clin Pharmacol Ther. 2008. PMID: 19238651

3

A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects.

Kidron M, Dinh S, Menachem Y, Abbas R, Variano B, Goldberg M, Arbit E, Bar-On H. Kidron M, et al. Among authors: arbit e. Diabet Med. 2004 Apr;21(4):354-7. doi: 10.1111/j.1464-5491.2004.01160.x. Diabet Med. 2004. PMID: 15049938

4

Oral heparin: status review.

Arbit E, Goldberg M, Gomez-Orellana I, Majuru S. Arbit E, et al. Thromb J. 2006 May 10;4:6. doi: 10.1186/1477-9560-4-6. Thromb J. 2006. PMID: 16686945 Free PMC article.

5

The physiological rationale for oral insulin administration.

Arbit E. Arbit E. Diabetes Technol Ther. 2004 Aug;6(4):510-7. doi: 10.1089/1520915041705929. Diabetes Technol Ther. 2004. PMID: 15321008 Review.

6

Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects.

Eldor R, Kidron M, Arbit E. Eldor R, et al. Among authors: arbit e. Diabetes Obes Metab. 2010 Mar;12(3):219-23. doi: 10.1111/j.1463-1326.2009.01153.x. Diabetes Obes Metab. 2010. PMID: 20151998

7

Oral insulin: the rationale for this approach and current developments.

Arbit E, Kidron M. Arbit E, et al. J Diabetes Sci Technol. 2009 May 1;3(3):562-7. doi: 10.1177/193229680900300322. J Diabetes Sci Technol. 2009. PMID: 20144296 Free PMC article. Review.

8

Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models.

Eldor R, Kidron M, Greenberg-Shushlav Y, Arbit E. Eldor R, et al. Among authors: arbit e. J Diabetes Sci Technol. 2010 Nov 1;4(6):1516-23. doi: 10.1177/193229681000400629. J Diabetes Sci Technol. 2010. PMID: 21129350 Free PMC article.

9

Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study.

Eldor R, Arbit E, Corcos A, Kidron M. Eldor R, et al. Among authors: arbit e. PLoS One. 2013 Apr 9;8(4):e59524. doi: 10.1371/journal.pone.0059524. Print 2013. PLoS One. 2013. PMID: 23593142 Free PMC article. Clinical Trial.

10

Oral Insulin Delivery in a Physiologic Context: Review.

Arbit E, Kidron M. Arbit E, et al. J Diabetes Sci Technol. 2017 Jul;11(4):825-832. doi: 10.1177/1932296817691303. Epub 2017 Feb 2. J Diabetes Sci Technol. 2017. PMID: 28654313 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

116 results

Search Page